Tagged with ART

Switzerland Basel-headquartered pharma giant Novartis announced its financial results for 2018 this week, showcasing full year net sales growth of five percent driven by the strong performance of the company’s pharmaceutical business unit and some strategic divestments.   In 2018 we reimagined Novartis. We took major steps towards becoming a medicines company…

Turkey Bucking a global trend for increased focus on outpatient and preventative care, Turkey is doubling down on hospital investment.   Throughout many of the healthcare systems in North America and Europe, there is an increasing emphasis on outpatient and preventative care. In terms of health economics, governments see a great benefit in…

France The Top 20 pharma companies in France, ranked by total turnover at ex-manufacturer prices for 2018. Swiss giant Novartis is in first place with a EUR 2.6 billion turnover, a full 89 percent of which came from the retail market. In second place is local champion Sanofi with a turnover…

France Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to the unprecedented wave of innovation that is revolutionizing the health industry.   In terms of research, we have invested EUR…

Spain Javier Alvarado, general manager of Mundipharma Spain, discusses his current priorities and the innovation the company is bringing to the market through a diversified portfolio. Furthermore, he points out the importance of long-term strategic partnerships for the company´s success and his future aspirations for the affiliate.   Of course, none…

Algeria Moncef Meklati, Merck’s general manager for North West Africa, discusses the company’s ambitions in the region, the key to successful joint ventures and evolving attitudes to chronic diseases in Algeria.   From the first day I started working for Merck, I’ve been impressed by the strong commitment of my team…

Opinion Emmanuel Fombu, Global Strategy and Digital Innovation Leader at Johnson & Johnson reflects on health professionals’ fears of AI and their place in the healthcare workforce of the future. Sure, robots might be better at carrying out specific operations or at carrying out monotonous tasks without tiring, but it’s the…

Turkey Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical industry and the government.   Through its Sandoz division, Novartis has been in Turkey since 1930 Can you introduce the…

Algeria Mourad Ishak, country president Novartis and general manager Sandoz Algeria reveals Novartis’ investment plan for local production, their “under one roof” project for the Novartis entities, and the key strategies to ensure sustainability within the Algerian market.   You’ve been in Algeria for four years. Can you enlighten our viewers…

innovation France is attempting to reposition itself as a globally competitive hub for artificial intelligence R&D, with significant state investment aiming to turn Paris into the next Palo Alto. With rapid digitalization and the ever-increasing invasion of artificial intelligence (AI) into all aspects of modern life, France has found itself left…

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…

UK The Top 15 pharmaceutical companies in the UK in the year up to March 2018 according to IQVIA data, ranked by market share. Pfizer leads the way with a whopping 8.2% market share, followed by Novartis with 6% and GSK with 5.3%